BESIX Watpac has completed CSL Seqirus’ new world‑class cell‑based influenza vaccine and antivenom manufacturing facility in Melbourne, a complex and secure development delivered ahead of schedule.
A significant addition to public health
The Australian‑owned and operated facility uses advanced technology to manufacture seasonal and pandemic influenza vaccines for Australia and beyond. As the only cell‑based influenza vaccine manufacturing facility in the Southern Hemisphere, it places Australia among just three countries worldwide with end‑to‑end capability to make advanced cell‑based influenza vaccines.
It is also the only manufacturing site in the world capable of producing Australia’s eleven antivenoms for venomous creatures and the human Q-Fever vaccine. The facility replaces CSL Seqirus’ long‑standing egg‑based vaccine site in Parkville, drawing a close to an 80‑year chapter of manufacturing innovation.
Expertise and strong collaboration
From the outset, BESIX Watpac established a one‑team approach with the client and partners. Combined with digital construction methods, this helped manage a highly technical, secure development smoothly and deliver ahead of programme. The project highlights the team’s deep experience in large‑scale, complex builds where quality and security are paramount.
It also reflects what can be achieved when everyone pulls in the same direction. Clear governance, open communication and shared objectives ensured a seamless journey from design through to delivery, resulting in outcomes that benefit both public health and industry.
Building sovereign capability
The facility strengthens a long‑term partnership with the Australian Government to boost sovereign manufacturing capability for pandemic influenza vaccines, antivenoms and the Q fever vaccine. In the event of an influenza pandemic, the facility and its associated network can rapidly produce more than 150 million vaccines in the first wave of manufacturing, helping safeguard Australia and contributing to global preparedness.
